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ABSTRACT
Purpose In order to attenuate the drug release rate, a single
freeze-thaw step was previously shown to convert encapsulat-
ed drug into a single nanocrystal within each liposome vesicle.
The goal of this study was to alter the nanocrystalline charac-
ter, and thus the drug encapsulation state and release profile,
by addition of surfactant prior to freeze-thaw.
Methods A liposomal ciprofloxacin (CFI) formulation was
modified by the addition of surfactant and frozen. After
thawing, these formulations were characterized in terms of
drug encapsulation by centrifugation-filtration, liposome
structure by cryo-TEM imaging, vesicle size by dynamic light
scattering, and in vitro release (IVR) performance.
Results The addition of increasing levels of polysorbate 20
(0.05 to 0.4%) or Brij 30 (0.05 to 0.3%) to the CFI prepara-
tions followed by subsequent freeze-thaw, resulted in a greater
proportion of vesicles without drug nanocrystals and reduced
the extent of growth of the nanocrystals thus leading to mod-
ified release rates including an increase in the ratio of non-
encapsulated to sustained release of drug.
Conclusions This study provides another lever to achieve the
desired release rate profile from a liposomal formulation by
addition of surfactant and subsequent freeze-thaw, and thus
may provide a personalized approach to treating patients.
KEY WORDS in vitro release . liposome . nanocrystal .
personalized medicine . surfactant
ABBREVIATIONS
API Active pharmaceutical ingredient
CF Cystic fibrosis
CFI Ciprofloxacin (liposomal) for inhalation
Fr/Th Freeze/Thaw
HBS HEPES buffered saline
HPLC High pressure liquid chromatography
HSPC Hydrogenated soy phosphatidylcholine
IVR In vitro release
MIC Minimum inhibitory concentration




TEM Transmission electron microscopy
INTRODUCTION
Liposomes are lipid vesicles, typically composed of bilayers of
phospholipids and sterols. In aqueous media, the two hydro-
phobic fatty acid tails of each phospholipid molecule are ori-
ented towards the center of the bilayer while the hydrophilic
head group is oriented towards the internal or external aque-
ous phase. Hydrophilic drugs can be loaded into the aqueous
interior of the vesicles while lipid soluble drugs can be associ-
ated with the lipid bilayer. A number of pharmaceutical prod-
ucts are now approved using liposomal formulations, and
manymore are in late-stages of clinical trials. Liposomal prod-
ucts have been designed to improve the safety and efficacy of
treatment, through modification of the pharmacokinetics and
biodistribution of the associated API (1, 2). Liposomes can also
incorporate targeting ligands, polyethylene glycol to increase
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the circulation lifetime, or be further modified to trigger drug
release in response to external stimuli (e.g., heat, light or ultra-
sound) or local stimuli (e.g., changes in pH) (1–3). Thus, lipo-
somes represent a versatile class of drug carriers which are
continuing to evolve to address new therapeutic opportunities.
These studies describe another step in the liposome evolution
process by expanding the formulation toolbox tomodulate the
drug release profile with only relatively minor changes in com-
position of the formulation. In particular, the key impact ap-
pears to be the modification of the solid state of the encapsu-
lated drug, in this example ciprofloxacin.
A liposomal ciprofloxacin formulation (CFI) composed of
80 to 90 nm unilamellar vesicles was used as the model for-
mulation in these studies (4). CFI containing >99% encapsu-
lated ciprofloxacin, termed Lipoquin® (Aradigm, Inc.,
Hayward, CA), and a formulation of 70% encapsulated cip-
rofloxacin and 30% non-encapsulated ciprofloxacin, termed
Pulmaquin® (Aradigm, Inc., Hayward, CA), have shown
promise in treating lung infections via inhalation delivery in
cystic fibrosis (CF) (4, 5) and non-CF bronchiectasis (NCFB)
(4, 6). Because unencapsulated ciprofloxacin is poorly soluble
in CFI at pH 6.0, Pulmaquin consists of a two-vial preparation
of CFI (liposomally-encapsulated ciprofloxacin) and non-
encapsulated ciprofloxacin (4). Pulmaquin has advanced into
late stages of clinical trials in NCFB (4). These formulations
have also shown efficacy in a number of biodefense applica-
tions including Yersinia pestis (4, 7), Francisella tularensis (4, 8), and
Q fever (4, 9). However, lung infections can differ in a number
of key attributes including the location of the infection in the
lungs (intracellular or extracellular), the presence of biofilm
and the sensitivity of the infectious agent to antibiotics.
Additionally, some antibiotics are ‘time-dependent’ and are
more effective the longer their concentration remains above
the bacteria’s minimum inhibitory concentration (MIC), while
others are ‘concentration-dependent’ and are more effective
the higher the peak concentration is above the MIC; e.g., ami-
noglycosides, while still others, like fluoroquinolones, may re-
quire a blending of these two elements (4, 10). Thus a combi-
nation of a bolus-release and sustained release profile may be
ideal for ciprofloxacin as was designed into the Pulmaquin
formulation. Depending on the specific infection and site of
disease, modifications to both the ratio of the bolus to the
sustained release component, and to the timing and duration
of the sustained release component itself, may be desirable to
improve efficacy.
The rate of drug release from liposomes can be modulated
by judicious choice of the phospholipid and the ratio of lipid to
sterol. Other factors can also affect the release profile includ-
ing the vesicle size distribution, the properties of the drug, the
method of drug loading into the liposomes, the location of the
drug within the vesicles, and ultimately the route of adminis-
tration and the resulting biological fluids that come into con-
tact with the liposomes (1, 2). While it is not typically possible
to modify the drug release rate once the liposome composition
has been defined and the formulation has beenmanufactured,
recently it was demonstrated for a liposomal ciprofloxacin
formulation that the drug release rate could be increased by
addition of polysorbate 20 (0.2 to 0.4%) or polysorbate 80
(0.2%) under conditions of osmotic swelling (11).
Alternatively, the release rate for the original liposomal cipro-
floxacin formulation could be decreased by conversion of the
encapsulated ciprofloxacin into nanocrystals following a single
freeze-thaw step (12). These two advances create options for
faster or slower releasing formulations and could be used to
personalize therapy so that the release profile optimally targets
the infectious agent, with minimum changes in the qualitative
composition or manufacturing processes.
The objective of these studies was to further investigate the
ciprofloxacin nanocrystal formation processes within the lipo-
somal formulation with the aim to identify procedures that
could be used to alter the size or shape of the crystalline drug
in a controlled manner. The formation of drug nanocrystals
results in lower soluble drug concentrations within the lipo-
somes which would be expected to reduce the rate of drug
release across the lipid membrane barrier as has previously
been shown for liposomal formulations of precipitated vincris-
tine (13) and doxorubicin (14). The mechanistic model for
release of precipitated doxorubicin sulfate from the liposomes
predicts that dissolution of the precipitated drug is not rate-
limiting; in other words, the driving force for release is the
soluble intra-vesicular drug concentration which remains con-
stant if the rate of drug dissolution matches the release of drug
from the liposomes (14). Forming ciprofloxacin nanocrystals
with different sizes or shapes, as will be attempted in these
studies, may provide evidence of whether drug dissolution is
rate-limiting for this liposomal system.
As noted above, the addition of nonionic surfactant to a
liposomal ciprofloxacin formulation caused transient drug
leakage from the vesicles in a concentration-dependent
manner but also affected the membrane permeability
resulting in faster releasing vesicles (11). Thus, one method
to further modulate the release profile of the nanocrystal-
line liposome formulations may be the addition of nonionic
surfactant prior to freeze-thaw. The presence of surfactant
may result in a reduction in the amount of encapsulated
drug; a smaller internal reservoir of drug may lead to
smaller drug crystals. If the dissolution step is rate-limiting,
then smaller drug crystals may result in a relatively faster
release profile than for larger drug crystals. In contrast, if
the dissolution step is not rate-limiting, then the change in
crystal structure may have no effect on the rate of drug
release from the nanocrystalline component. The addition
of surfactant followed by freeze-thaw may provide addi-
tional levers to adjust the ratio of the drug bolus to the
sustained release profile of a nanocrystalline liposomal cip-
rofloxacin formulation.
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MATERIALS AND METHODS
Materials
Liposomes containing 50 mg/ml ciprofloxacin (expressed in
terms of ciprofloxacin hydrochloride) in a pH 6.0 histidine
buffer were manufactured by Northern Lipids Inc. (Burnaby,
BC, Canada) and Sigma-Tau (Indianapolis, IN). The following
materials were used for the preparation, characterization or
analysis of the liposomal ciprofloxacin (CFI) formulations: su-
crose (Sigma-Aldrich (St. Louis, MO)), HEPES, free acid
(Avantor (Center Valley, PA)), sodium chloride (Amresco
(Solon, OH)), HPLC grade methanol (Fisher Scientific (Fair
Lawn, NJ)), triethylamine (TEA, JT Baker (USA)), polysorbate
20 (VWR Int. (West Chester, NJ)), polyethylene glycol dodecyl
ether (Brij 30 (Sigma-Aldrich (Australia))), Donor Adult Bovine
Serum (HyClone (Logan, Utah)), and Nanosep centrifugal fil-
tration devices, 10 K and 30 K molecular weight (Pall




The preparation of CFI, an aqueous dispersion of ~80 nm li-
posomes containing cholesterol and hydrogenated soy phospha-
tidylcholine (HSPC), has been reported previously (4, 11, 15).
Briefly, multilamellar liposomes were extruded through mem-
branes to produce predominantly 80 to 90 nm sized unilamellar
liposomes that were subsequently actively loaded with ciproflox-
acin (4, 16, 17). Any unencapsulated ciprofloxacin was removed
by diafiltration resulting in >99% encapsulated ciprofloxacin at
a target concentration of 50 mg/ml.
Freeze-Thaw Studies to Create Nanocrystals
Formulations of 50 mg/ml CFI were diluted with various com-
binations of sucrose, trehalose, polysorbate 20, Brij 30 or water
to produce liposomal formulations targeting a ciprofloxacin
concentration of 12.5 mg/ml. One ml aliquots were trans-
ferred to either plastic Eppendorf tubes or HPLC glass vials
and frozen in either liquid nitrogen or by storing for at least
20 h in a −50°C freezer. The samples were thawed at room
temperature and vortexed to ensure homogeneity prior to sub-
sequent evaluation of physical appearance, drug encapsula-
tion, vesicle size, in vitro release, or cryo-TEM analysis.
Following thawing, stability to freeze-thaw was confirmed by
visual clarity. The presence of precipitated matter,
representing agglomerated vesicles, indicated that the formu-
lation was not stable to freeze-thaw.
Vesicle Size
The vesicle size of each sample was measured using a
Submicron Particle Sizer Autodilute Model 370 (Nicomp,
USA). The measurements were made using the following set-
tings: run time: 5 min; viscosity: 0.933; refractive index: 1.333;
temperature: 23°C; scattering angle: 90; intensity set point: 300
KHz; channel width: 10 μsec; mode: vesicle; Gaussian distri-
bution. Each CFI sample was diluted with saline to a concen-
tration of ~2 mg/ml liposomes (1 mg/ml ciprofloxacin), and
0.5 ml was pipetted into a disposable culture tube (Kimble
Glass Inc., USA) for analysis. The mean vesicle size and stan-
dard deviation (SD) of the distribution are recorded.
Drug Encapsulation
Centrifugal filtration was performed using Nanosep Omega
centrifugation devices (Pall Corporation, Ann Arbor,MI) with
modified polyethersulfone membrane filters of 10,000 or
30,000 molecular weight cut-offs to separate liposomal encap-
sulated drug from non-encapsulated drug (18). Briefly, each
sample was diluted with acetate buffer (50 mM sodium ace-
tate, 145 mM NaCl, pH 4.0) to ~0.625 mg/ml ciprofloxacin
and 400 μl was transferred to the centrifugation device and
centrifuged for 10 min at 10,000 rpm (8,100 g). The non-
encapsulated drug was recovered in the filtrate and quantified
by HPLC. The total amount of ciprofloxacin was also deter-
mined by HPLC by diluting the original CFI sample twenty-
fold into 80% methanol to solubilize the liposomes. The per-
cent drug encapsulation in each sample was calculated by
dividing the non-encapsulated ciprofloxacin by the total cip-
rofloxacin and multiplying by 100%.
In Vitro Release (IVR) Assay
The rate and extent of release of ciprofloxacin from liposomes
was measured in an IVR assay (18). Briefly, the CFI samples
were diluted with HEPES Buffered Saline (HBS: 20 mM
HEPES, 145 mMNaCl, pH 7.4) to a ciprofloxacin concentra-
tion of 50 μg/ml, mixed with chilled (2–8°C) bovine serum
(Hyclone) to a ciprofloxacin concentration of 25 μg/ml and
placed in a shaking water bath (Techne, TSBS40
(Staffordshire, UK)) at 37°C and 150 rpm. Samples in dupli-
cate were removed after incubation for 30, 60, 120 and
240 min, diluted to a ciprofloxacin concentration of
12.5 μg/ml with chilled (2–8°C) HBS and immersed in an
ice-water bath to terminate any further release of encapsulat-
ed drug. The amount of non-encapsulated (released) and total
drug was measured by centrifugal filtration as described in the
drug encapsulationmethodology section with one adjustment:
The presence of the serum in the CFI sample during centrif-
ugal filtration reduces the recovery of non-encapsulated drug
from 100 to 93% so the non-encapsulated drug value is
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normalized by dividing by 0.93 (18). Due to the presence of
substantial unencapsulated drug in some formulations at
T0min, the normalized initial release rate was calculated by
measuring the initial release, T30min-T0min, divided by the
total possible release, 100-T0min, and converting to a percent-
age: 100* (T30-T0)/(100-T0).
Cryogenic Transmission Electron Microscopy (Cryo-TEM)
To obtain visual images of the liposomal ciprofloxacin formu-
lations and confirm the presence or absence of drug
nanocrystals, and the state of liposome morphology, cryo-
TEM analysis was performed either prior to freezing
(control) or after freeze-thaw (experimental) using a JEOL
2100 (Tokyo, Japan) instrument operated at 200 kV. In one
set of studies, the kinetics of nanocrystal formation were eval-
uated by performing cryo-TEM analysis immediately after
thawing, ~45 min, ~2 h or up to ~16 h after thawing. The
control and the thawed CFI samples were diluted to
~5 mg/ml (10 mg/ml liposomes) with water and 3 μl of
each sample was applied to a glow discharge Quantifoil
carbon grid (Jena, Germany) in a chamber controlled to
22°C and 100% RH. Grids were blotted once with filter
paper, at a blotting angle of 2 mm for 2 s, and vitrified
by plunging into liquid ethane using a Vitrobot (F.E.I.,
Eindhoven, Netherlands). The vitrified samples were stored
in liquid nitrogen prior to cryo-TEM analysis.
High Performance Liquid Chromatography (HPLC) Assay
of Ciprofloxacin
An isocratic reverse phase HPLC method operated at a flow
rate of 0.9 ml/min was used to quantify the amount of cipro-
floxacin in each sample as described previously (11, 18). The
mobile phase was a mixture of 0.5% TEA in water, pH 3.0
and 100% methanol (83:17 v/v). Separation was performed
using a Nucleosil C-18 column (5 μm, 4.6 × 150 mm,
Canadian Life Science, CA) protected with a Nucleosil C-18
guard column (4 × 3.0 mm, Phenomenex, USA) both equili-
brated at 35°C. Ciprofloxacin was quantified at 277 nm.
Statistical Analysis
The in vitro release profiles were compared using difference
factor (f1) and similarity factor (f2) analysis. Similarity factor
analysis is recommended by the FDA for modified release
solid oral dosage forms (19), with f2 values greater than 50
(50 to 100) indicating similarity. Likewise, difference factor
values (f1) less than 15 (0 to 15) indicate no difference (20).
Only the similarity factors are reported here because there
was complete agreement between the similarity factor analysis
and the difference factor analysis. That is, in every instance
that the f2 values indicated similarity (f2 > 50), the f1 values
indicated no difference (f1 < 15), and in every instance when
the f2 values indicated lack of similarity (f2 < 50), the f1 values
indicated a difference (f1 > 15).
RESULTS
Effect of Addition of Surfactant to CFI or Empty
Liposomes
Previously we demonstrated formation of drug nanocrystals
following freeze thaw for three liposomal ciprofloxacin (CFI)
formulations each containing sucrose external to the vesicles,
but varying in their internal sucrose concentrations (0, 50 or
150 mM sucrose) (12). The presence of the drug nanocrystals
led to a reduction in the in vitro release rate (12). In these
experiments the goal was to evaluate the addition of surfactant
to the CFI formulation to determine if drug nanocrystals
would still form after freeze-thaw, and whether the presence
of the surfactant would result in modified properties due to
interactions of the surfactant with the lipid membrane or a
modification to the nanocrystal character.
CFI formulations at 12.5 mg/ml were prepared containing
0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35 or 0.4% polysorbate 20,
and 45, 67.5 or 90 mg/ml sucrose to result in a ratio of cryo-
protectant to lipid of 2:1, 3:1 and 4:1 (w/w), respectively. CFI
formulations at 12.5 mg/mL were also prepared containing
0.05, 0.1, 0.2, and 0.3% Brij 30 and 90 mg/ml sucrose to
result in a ratio of cryoprotectant to lipid of 4:1 (w/w).
Samples for each of these conditions were evaluated for phys-
ical appearance, vesicle size and drug encapsulation pre and
post freeze-thaw. A subset of the CFI samples at 12.5 mg/ml
containing polysorbate 20 or Brij 30 was then evaluated for
IVR and cryo-TEM analysis.
A number of additional surfactants were tested including
polysorbate 80, sorbitan monolaurate (SPAN 20), sorbitan
monooleate (SPAN 80), poloxamer L44 and poloxamer
L62, without success: CFI formulations containing sucrose
and these surfactants were unstable to the freeze-thaw process,
resulting in agglomerated lipid deposits in the vials.
Physical Appearance Pre and Post Freeze-Thaw
Prior to freeze-thaw, each of the 28 samples at 12.5mg/ml CFI
containing polysorbate 20 (n= 24) or Brij 30 (n= 4) retained an
appearance similar to that for CFI diluted in sucrose alone;
there was no precipitated material after the addition of surfac-
tant. Immediately after freeze-thaw, all of the samples retained
clarity indicating stability to freeze-thaw; however, the samples
with only 2:1 (w/w) sucrose to lipid started to become turbid
over the subsequent 30 min, suggesting inadequate physical
stability post freeze-thaw. The presence of surfactant, at least
in the samples with adequate cryoprotectant (≥3:1 sucrose to
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lipid (w/w)), did not appear to compromise the stability of the
liposomes in response to freeze-thaw. For the samples with 3:1
and 4:1 (w/w) sucrose to lipid, while they were physically stable
to freeze-thaw, a different instability phenomenon was ob-
served over the subsequent 24 h. The samples became birefrin-
gent under light microscope displaying the presence of long
drug crystals external to the liposomes. Presumably, encapsu-
lated drug was released from the liposomes post freeze-thaw
resulting in an external drug concentration that exceeded the
solubility limit in the pH 6.0 buffer which led to drug crystalli-
zation outside the liposomes (21). The CFI samples containing
0.05, 0.10, 0.15 and 0.20% polysorbate 20 and all CFI samples
containing Brij 30 retained clarity for the longest period post
freeze-thaw suggesting that theymay have lost the least amount
of encapsulated drug.
Vesicle Size Before and After Freeze-Thaw
CFI Containing Polysorbate 20
The mean vesicle size before and after freeze-thaw for the
12.5 mg/ml CFI formulations containing 2:1, 3:1, or 4:1 su-
crose to lipid, and 0.05 to 0.4% polysorbate 20, is reported in
duplicate in Table I. The addition of polysorbate 20 to the
CFI formulation containing sucrose resulted in a minimal in-
crease (up to 4 nm) in the mean vesicle size compared to the
control CFI formulation without polysorbate 20 or sucrose
(91.0 nm). This result is consistent with a previous report of
a small increase in vesicle size upon addition of polysorbate 20
to the CFI formulation without sucrose (11). After freeze-
thaw, there was a significant increase in mean vesicle size of
25 to 50 nm for the liposomal ciprofloxacin samples contain-
ing the least amount of polysorbate 20 (0.05%, Fig. 1) but this
is less than the 59 nm vesicle size increase observed for CFI in
the absence of polysorbate 20 (Table I). Higher concentrations
of polysorbate 20 resulted in even smaller increases in vesicle
size (Fig. 1). For example, there was an increase of only 2 to
8 nm in mean vesicle size for the CFI samples containing 0.15
to 0.35% polysorbate 20 (Fig. 1). Thus, the presence of sur-
factant impacts the final vesicle size following freeze-thaw.
The higher surfactant concentrations may reduce the pool of
drug that is available within the vesicles to form nanocrystals
and thus influence the ultimate size of the vesicle following
nanocrystal formation and growth.
CFI Containing Brij 30
The mean vesicle size, before and after freeze-thaw, for the
12.5 mg/ml CFI formulations containing 0.05, 0.1, 0.2, and
0.3% Brij 30 were only performed using the highest cryopro-
tectant concentration of 90 mg/ml sucrose (Table I). Similar
to what was observed for CFI containing polysorbate 20, there
was an increase in mean vesicle size after freeze-thaw.
However, while the presence of moderate amounts of polysor-
bate 20 (e.g., 0.15 to 0.25%) resulted in very small increases in
mean vesicle size of 3 to 5 nm, for Brij 30 there was a large
increase in mean vesicle size (of 20 to 40 nm) across the entire
range of 0.05 to 0.3% Brij 30, suggesting a different response
to freeze-thaw than for the CFI samples containing polysor-
bate 20 (Fig. 1).
Drug Encapsulation Before and After Freeze-Thaw
CFI Containing Polysorbate 20
Previously it was shown that the addition of polysorbate 20
(0.2 to 0.4%) to liposomal ciprofloxacin vesicles in a
hyperosmotic environment caused large losses in encapsulated
drug of between 20 and 40% due to osmotic swelling of the
liposomes during association of the surfactant with the lipo-
somemembrane (11). In contrast, in these studies the presence
of sucrose in the external buffer was expected to limit the
amount of encapsulated drug loss upon addition of surfactant
to the 12.5 mg/ml CFI, and that was indeed the case. Only a
small loss in drug encapsulation (<10%) resulted from the
addition of up to 0.4% polysorbate 20 to 12.5 mg/mL CFI
containing 90 mg/mL sucrose (Fig. 2). Similar encapsulation
profiles were also observed for the CFI formulations contain-
ing 45 or 60 mg/mL sucrose upon addition of polysorbate 20
(data not shown).
After freeze-thaw at −50°C or in liquid nitrogen, increasing
concentrations of surfactant led to greater loss in drug encapsu-
lation, indicating release of encapsulated drug in response to the
stress of freeze-thaw (Fig. 2). Samples containing the most poly-
sorbate 20 (0.35 to 0.4%) had the greatest decrease in drug
encapsulation to ~55%, via either freezing method (Fig. 2).
There was general agreement with the two freezing methods
except for CFI samples containing the lowest concentration of
surfactant, 0.05% polysorbate 20. For that sample, freezing in
liquid nitrogen produced results in line with the general trend
whereas freezing at−50°C resulted inmore variable and greater
losses in drug encapsulation (Fig. 2).
CFI Containing Brij 30
Prior to freeze-thaw the Brij 30 surfactant did not cause mean-
ingful changes in drug encapsulation with less than 3% drug
loss even for CFI samples containing the highest amount
(0.3%) of Brij 30 (Fig. 3). After freeze-thaw, there was a signif-
icant loss in encapsulated drug ranging up to ~20% for CFI
containing 0.3%Brij 30 surfactant (Fig. 3). Compared to poly-
sorbate 20, Brij 30 appeared to be less destabilizing to the
liposomal ciprofloxacin vesicles during the freeze-thaw pro-
cess resulting in a greater retention of encapsulated drug.
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Cryo-TEM Imaging to Evaluate the Kinetics
and Morphology of Nanocrystal Formation
CFI Containing Polysorbate 20
Cryo-TEM imaging was undertaken to determine if the for-
mation of nanocrystals within the vesicles occurred post
freeze-thaw in liquid nitrogen for the CFI formulations con-
taining surfactant as was previously reported for the CFI for-
mulations without surfactant, and if so, the effect of surfactant
concentration on crystal structure (12). In order to understand
the kinetics and stability of the nanocrystal formation process,
12.5 mg/ml CFI samples containing surfactant were analyzed
by cryo-TEM immediately after thawing and then at various
time points up to 17 h post freeze-thaw in liquid nitrogen. To
characterize the effect of different surfactant levels on the
structures of the nanocrystals and the liposome morphology,
CFI samples contained 4:1 (w/w) sucrose to lipid and either
0.05, 0.1 or 0.2% polysorbate 20. The presence of
nanocrystals was observed in every sample, even immediately
after thawing (Fig. 4a, d and g), indicating that the formation
of nanocrystals was very rapid. For all conditions, the lipo-
somes retained their unilamellar structure.
Similar to the cryo-TEM imaging of nanocrystalline CFI in
the absence of surfactant (12), in the presence of only 0.05%
polysorbate 20 the liposomes were elongated with the vast
majority of liposomes showing the presence of internalized
nanocrystalline structures (Fig. 4a). After up to 17 h post
freeze-thaw, there did not appear to be a qualitative change
in the cryo-TEM images with the vesicles remaining elongated
and almost all of them continuing to show the presence of
nanocrystalline structures (Fig. 4b–c).
For the liposomes containing 0.1% polysorbate 20, the
nanocrystalline structures also formed immediately, but the
liposomes remained fairly circular in appearance (Fig. 4d) com-
parable in size to the unfrozen CFI control images (12, 15).
There was a small minority of liposomes without any
nanocrystals, and these were predominantly of lighter density
than for the control unfrozen CFI images but of comparable
density to the empty liposomes (12), suggesting that they no
longer contained a significant amount of drug. The proportion
of ‘empty’ vesicles did not appear to change over time for the
CFI samples containing 4:1 (w/w) sucrose to lipid whereas for
the CFI samples containing 3:1 (w/w) sucrose to lipid the pro-
portion of ‘empty’ liposomes appeared to increase over the 17 h
time period (data not shown).
Table I The Vesicle Size
Distribution Before and After
Freeze-Thaw At −50°C of the
12.5 mg/ml CFI Formulations,
Containing 45, 67.5, or 90 mg/ml
Sucrose (representing 2:1, 3:1, or
4:1 sucrose to lipid (w/w)) and
Varying Amounts of Polysorbate 20
or Brij 30
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Surfactant (%) 2:1 Sucrose:Lipid (w/w) 3:1 Sucrose:Lipid (w/w) 4:1 Sucrose:Lipid (w/w)
Before After Before After Before After
Polysorbate 20
0 ND 91.0 [25.7] 150.0 [75.5] ND
0.05 91.5 [25.3] 124.1 [53.5] 90.9 [27.2] 116.0 [43.5] 91.4 [25.3] 115.9 [43.0]
139.3 [67.5] 138.7 [72.0] 142.0 [68.8]
0.10 91.4 [27.3] 103.7 [34.4] 91.1 [23.9] 104.2 [32.7] 92.0 [16.6] 102.0 [34.0]
117.5 [41.4] 113.4 [40.8] 108.0 [39.5]
0.15 92.3 [29.0] 97.1 [32.3] 91.8 [24.5] 95.0 [32.6] 92.4 [23.5] 96.6 [27.1]
99.7 [36.7] 100.0 [32.3] 98.0 [27.8]
0.20 92.8 [22.3] 95.3 [34.7] 91.9 [28.0] 95.9 [31.2] 93.7 [23.7] 97.0 [34.5]
98.2 [29.8] 96.1 [34.2] 95.2 [33.0]
0.25 93.0 [25.4] 96.9 [29.6] 93.8 [22.8] 98.0 [28.4] 93.0 [24.7] 97.9 [22.6]
97.6 [33.6] 96.0 [33.4] 98.4 [28.8]
0.30 93.7 [25.2] 98.4 [28.7] 93.7 [22.0] 100.0 [29.2] 95.4 [20.3] 99.5 [30.3]
99.0 [27.9] 99.2 [18.0] 100.1 [29.7]
0.35 93.9 [25.0] 99.7 [27.4] 94.1 [25.4] 100.9 [32.0] 93.3 [18.2] 100.7 [33.0]
100.1 [32.6] 100.2 [32.0] 100.4 [34.3]
0.40 93.9 [23.1] 99.6 [34.2] 94.4 [25.9] 101.5 [36.0] 95.3 [28.9] 103.4 [29.0]
100.6 [38.3] 103.3 [33.1] 105.2 [27.7]
Brij 30
0.05 ND 92.1 [22.7] 121.8 [45.0]
128.5 [53.0]
0.10 93.7 [23.4] 118.3 [35.2]
130.3 [60.3]
0.20 94.4 [22.4] 124.8 [43.2]
130.6 [64.3]
0.30 96.5 [23.3] 118.0 [44.9]
125.4 [58.5]
Vesicle size data are reported as the mean (in nm) and [SD]. Duplicate freeze-thaw experiments were performed to
characterize the repeatability of the effect of freeze-thaw on the size of the liposomes. ND Not Done
For the CFI samples containing 0.2% polysorbate 20, the
observations were similar to those described for the CFI sam-
ples containing 0.1% polysorbate 20, except that there were an
even greater proportion of empty liposomes initially and that
proportion increased over the 17 h time period post freeze-
thaw. While it is not possibly to strictly quantify the proportion
of empty liposomes versus those containing nanocrystals by cryo-
TEM imaging due to varying film thickness and sorting mech-
anisms in the cryo-TEM sample matrix (22), the population of
empty liposomes was estimated to be ~40% of the total lipo-
somes in the cryo-TEM images for the CFI samples containing
0.2% polysorbate 20 after freeze-thaw.
CFI Containing Brij 30
CFI samples at 12.5 mg/ml containing 90 mg/ml sucrose and
either 0.05 or 0.25% Brij 30 were analyzed by cryo-TEM
imaging before and after freeze-thaw in liquid nitrogen to ob-
serve the effect on vesicle morphology and the existence of
nanocrystals. These two surfactant concentration levels were
chosen to bracket both the low and high end of the surfactant
range. The cryo-TEM images of the control CFI formulation
containing 0.05% Brij 30 (Fig. 4j) or 0.25% Brij 30 (data not
shown) were comparable to that for the control CFI without
surfactant (12), displaying unilamellar liposomes around 80–
90 nm in size. After freeze-thaw, nanocrystals were observed
in both samples containing Brij 30 (Fig. 4k and l), similar to
what was observed for the studies with polysorbate 20; howev-
er, the liposomes generally remained unilamellar in structure.
For the liposomes containing 0.05% Brij 30, the nanocrystal-
line structures were observed within elongated liposomes
Fig. 2 The effect of addition of polysorbate 20 on the state of ciprofloxacin
encapsulation for 12.5 mg/ml CFI containing 90 mg/mL sucrose (4:1 sucrose to
lipid (w/w)) before and after freeze-thaw in either liquid nitrogen or at−50°C.
CFI at 50 mg/ml ciprofloxacin was diluted to a final concentration
of ~12.5 mg/ml with sucrose (180 mg/ml), water, and polysorbate 20 (1 or
10%) to achieve a final surfactant concentration of 0.05, 0.1, 0.15, 0.2, 0.25,
0.3, 0.35 or 0.4%. After vortexing and allowing each sample to equilibrate for at
least 30min, the ciprofloxacin encapsulation state was determined by centrifugal
filtration. Red circles are prior to freeze-thaw, green squares are after freeze-
thaw at−50°C and blue diamonds are after freeze-thaw in liquid nitrogen. Each
data point is a single measurement and the lines represent the average.
Fig. 3 The effect of addition of Brij 30 on the state of ciprofloxacin encapsu-
lation for 12.5 mg/ml CFI containing 90 mg/mL sucrose (4:1 sucrose to lipid
(w/w)) before and after freeze-thaw at−50°C. CFI at 50 mg/ml ciprofloxacin
was diluted to a final concentration of ~12.5 mg/ml with sucrose (180 mg/ml),
water, and Brij 30 (1 or 10%) to achieve a final surfactant concentration of 0.01,
0.05, 0.1, 0.2, and 0.3%. After vortexing and allowing each sample to equili-
brate for at least 30 min, the ciprofloxacin encapsulation state was determined
by centrifugal filtration. Red circles are prior to freeze-thaw and green squares
are after freeze-thaw at −50°C. Each data point represents a single measure-
ment and the lines represent the average.
Fig. 1 The increase in the mean vesicle size after freeze-thaw for the
12.5 mg/ml CFI formulations containing polysorbate 20 and either 45,
67.5, or 90 mg/ml sucrose (representing 2:1, 3:1, or 4:1 sucrose to lipid
(w/w)) or Brij 30 and 90 mg/mL sucrose (representing 4:1 sucrose to lipid
(w/w)). The increase in mean vesicle size after freeze-thaw is calculated from
the data reported in Table I.
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(Fig. 4k), not unlike what was observed in the studies with
0.05% polysorbate 20. In contrast, using 0.25% Brij 30, while
the liposomes were more circular in shape, they were larger
than observed in the studies with 0.1 to 0.2% polysorbate 20,
consistent with the differences observed in vesicle size by DLS
(Table I). More empty liposomes were also observed in the
cryo-TEM images for the higher Brij 30 concentration
(Fig. 4l versus k), similar to what was observed for polysorbate
20 (Fig. 4g versus d).
Effect on IVR Profile
CFI Containing Polysorbate 20
To determine how the presence of the nanocrystals affected
the drug release rate, the IVR profiles of the 12.5 mg/ml CFI
formulation containing 90 mg/ml sucrose and either 0.05, 0.1
or 0.2% polysorbate 20, pH 6.0 were obtained after freeze-
thaw at −50°C and compared to that for the control CFI
which was not frozen (Fig. 5). The IVR profiles after freeze-
thaw for all three CFI formulations containing surfactant
demonstrated slower initial release rates compared to the un-
frozen control, consistent with the presence of drug
nanocrystals within the vesicles. There was an initial Bburst^
of 17, 14 and 35% drug at T = 0 for the formulations con-
taining 0.05, 0.1 and 0.2% polysorbate 20, respectively, gen-
erally consistent with the trend in loss of encapsulated drug
reported earlier after freeze-thaw at −50°C (Fig. 2). None of
the IVR profiles for the experimental samples achieved com-
plete release of drug over the 240 min period, but achieved 83
to 89% release by the last time point in the assay.
By visual inspection, there appears to be a meaningful dif-
ference in the release profiles for all three polysorbate 20-










Fig. 4 Cryo-TEM micrographs of
12.5 mg/ml CFI, 90 mg/ml sucrose,
pH 6.0 liposomes after freeze-thaw
in liquid nitrogen. The scale bar in
the bottom left-hand corner of
micrographs A, C, E, G, H and K is
200 nm, in micrographs B, F, I, J and
L is 100 nm and in micrograph D is
50 nm. (a) 0.05% polysorbate 20,
45 min post freeze-thaw; (b)
0.05% polysorbate 20, 140 min
post freeze-thaw; (c) 0.05%
polysorbate 20, 16.7 h post freeze-
thaw; (d) 0.1% polysorbate 20,
40 min post freeze-thaw; (e) 0.1%
polysorbate 20, 140 min post
freeze-thaw; (f) 0.1% polysorbate
20, 16.7 h post freeze-thaw; (g)
0.2% polysorbate 20, <1 min post
freeze-thaw; (h) 0.2% polysorbate
20, 120 min post freeze-thaw; (i)
0.2% polysorbate 20, 16.3 h post
freeze-thaw; (j) 0.05% Brij 30,
prior to freeze-thaw; (k) 0.05% Brij
30< 30 min after freeze-thaw; (l)
0.25% Brij 30 < 30 min after
freeze-thaw. The dashed arrows in
C show ice artifacts introduced
during sample preparation. All
samples were applied at a
concentration of ~10 mg/ml
liposomes.
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the control CFI formulation (without nanocrystals). Similarity
factor (f2) analysis was used to quantify the difference between
the profiles, with an f2 value below 50 indicating a significant
difference (Table II). Post freeze-thaw, the similarity factor
analysis confirmed that all three CFI formulations containing
polysorbate 20 after freeze-thaw had distinct IVR profiles
compared to the unfrozen control formulation, with similarity
factors less than 50: 37.2, 34.6 and 34.9 for the formulations
containing 0.05, 0.1 and 0.2% polysorbate 20, respectively
(Table II). The only profiles found to be similar to each other
by similarity factor analysis were for those containing 0.05 and
0.1% polysorbate 20 after freeze-thaw.
The addition of polysorbate 20 to CFI causes both an in-
crease in non-encapsulated drug and a change in nanocrystal-
line character after freeze-thaw; i.e., shorter crystals within
more circular vesicles. To better understand the influence of
these changes in the nanocrystalline structure on release rate,
another freeze-thaw study was performed this time including
the CFI formulation without polysorbate 20 and using liquid
nitrogen to freeze the samples, to mimic the conditions used
for cryo-TEM analysis.
The IVR profiles after freeze-thaw for the CFI formulations
with or without polysorbate 20 again demonstrated slower ini-
tial release rates compared to the unfrozen control (Fig. 6),
similar to the results shown previously in Fig. 5. The nanocrys-
talline profiles also demonstrate a statistically significant differ-
ence to the unfrozen control CFI using similarity factor analysis
(Table III). The amount of unencapsulated drug initially was
0.2, 9.1 and 22.2% for the formulations containing none, 0.05,
and 0.1% polysorbate 20, respectively, consistent with the
trend in loss of encapsulated drug reported earlier after liquid
nitrogen freeze-thaw (Fig. 2). To compare just the contribution
of the encapsulated drug to the rate of release, the normalized
initial rate of release was calculated. The normalized initial rate
of release was 42, 22, 22 and 16%, respectively, for the CFI
control and the three CFI formulations containing none, 0.05
and 1% polysorbate 20 after freeze-thaw. The normalized ini-
tial rate of release for all three nanocrystalline formulations was
about half that of the CFI control. Thus, while the three CFI
formulations have different nanocrystalline structures (Fig. 4
and (12)), there is little change to the initial rate of drug release
compared to each other.
Another way to compare the release profiles from the en-
capsulated drug alone is to take the release profile for the
nanocrystalline formulation without polysorbate 20 and sim-
ulate the addition of 10 or 20% unencapsulated drug to the
profile (to match the T0min for the two formulations contain-
ing polysorbate 20). The contribution from the nanocrystals is
also reduced by 10 or 20%, respectively, in this simulation so
that the total drug release still represents 100%. These profiles
are shown by the yellow and green dashed lines in Fig. 6. The
simulated profile for the nanocrystalline formulation with
10% unencapsulated drug very closely matches that for the
CFI formulation containing 0.05% polysorbate 20 with a sim-
ilarity factor (f2) of 92.3, very near 100. The simulated profile
for the nanocrystalline formulation with 20% unencapsulated
drug is not statistically different from that for the CFI formu-
lation containing 0.1% polysorbate 20 with a similarity factor
(f2) of 69.2, exceeding 50. Discounting the presence of the
Fig. 5 Evaluation of the effect of freeze-thaw at−50°C on the IVR profiles of
CFI formulations at pH 6.0 containing 90 mg/ml sucrose and polysorbate 20
after freeze-thaw. The CFI formulations (at 12.5 mg/ml) were diluted to
50 μg/ml ciprofloxacin in HEPES buffered saline (HBS) prior to a 1:1 dilution
in bovine serum to measure the release of ciprofloxacin after incubation at
37°C for up to 4 h. IVR profiles are shown for the CFI control (no freeze-thaw,
blue diamonds), CFI containing 0.05% polysorbate 20 after freeze-thaw (red
squares), CFI containing 0.1% polysorbate 20 after freeze-thaw (green trian-
gles), and CFI containing 0.2% polysorbate 20 after freeze-thaw (yellow
circles). Duplicate samples were analyzed at each time point.
Table II Similarity Factor Analysis (f2) for CFI Formulations Containing Various Amounts of Polysorbate 20 After Freeze-Thaw at−50°C Versus the CFI Control
Shaded cells indicate lack of similarity
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initial unencapsulated drug, these results confirm that the rate
of encapsulated drug release from the three nanocrystalline
liposomal formulations is not statistically different. This result
also suggests that the permeability of the lipid membrane was
unaffected by the presence of 0.05 or 0.1% polysorbate 20,
and is consistent with previous observations (11).
Table III Similarity Factor Analysis (f2) for CFI Formulations Containing Various Amounts of Polysorbate 20 After Freeze-Thaw in Liquid Nitrogen Versus the CFI
Control
Shaded cells indicate lack of similarity
Fig. 6 Evaluation of the effect of freeze-thaw in liquid nitrogen on the IVR
profiles of CFI formulations at pH 6.0 containing 90 mg/ml sucrose and 0,
0.05 or 0.1% polysorbate 20 after freeze-thaw. The CFI formulations (at
12.5 mg/ml) were diluted to 50 μg/ml ciprofloxacin in HEPES buffered saline
(HBS) prior to a 1:1 dilution in bovine serum to measure the release of
ciprofloxacin after incubation at 37°C for up to 4 h. IVR profiles are shown
for the CFI control prior to freeze-thaw (blue diamonds) or after freeze-thaw
(red circles), CFI containing 0.05% polysorbate 20 after freeze-thaw (green
diamonds), CFI containing 0.1% polysorbate 20 after freeze-thaw (yellow
triangles). Duplicate samples were analyzed at each time point. Two simulated
curves were generated by adjusting the release from the CFI sample without
polysorbate 20 after freeze-thaw by assuming the addition of either 10% free
drug (green dashed line) or 20% free drug (yellow dashed line) and normalizing
the total drug release to 100%.
Fig. 7 Evaluation of the effect of freeze-thaw at−50°C on the IVR profiles of CFI
formulations at pH 6.0 containing 90 mg/ml sucrose and Brij 30 before (a) and
after (b) freeze-thaw. The 12.5 mg/ml CFI formulations were diluted to 50 μg/ml
ciprofloxacin inHEPES buffered saline (HBS) prior to a 1:1 dilution in bovine serum
to measure the release of ciprofloxacin after incubation at 37°C for up to 4 h. IVR
profiles are shown for the CFI control (no freeze thaw, blue diamonds), CFI
containing 0.05% Brij 30 (red squares), CFI containing 0.1% Brij 30 (green
triangles), CFI containing 0.2% Brij 30 (orange circles), and CFI containing 0.3%
Brij 30 (purple squares). Duplicate samples were analyzed at each time point.
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CFI Containing Brij 30
Prior to freeze-thaw, the presence of 0.05% Brij 30 in the CFI
formulation had a negligible effect on the IVR profile com-
pared to the control CFI sample (Fig. 7a). The samples con-
taining 0.1, 0.2, or 0.3% Brij 30 had slightly faster initial
release rates at the 30 min time point (Fig. 7a), with the fastest
initial release rate for the CFI sample with the highest surfac-
tant concentration. The addition of Brij 30 surfactant to lipo-
somal ciprofloxacin does not result in a significant change in
the IVR profile when evaluated by similarity factor analysis
(Table IV). All of the similarity factor values exceed 72, above
the key value of 50, indicating that there is not a meaningful
difference between any of the IVR profiles for the various
samples prior to freeze-thaw.
After freeze-thaw, all CFI samples containing Brij 30
showed an increase in non-encapsulated drug at the T =
0 min time point in the IVR assay, ranging from 6 to 21%
(Fig. 7b), not too dissimilar from the drug encapsulation values
reported in Fig. 3. This initial Bburst^ was followed by a
slower initial release profile compared to that for the unfrozen
control CFI sample, as would be expected if drug nanocrystals
had formed as a result of freeze-thaw (Fig. 7b). All samples
approached complete drug release by the last time point in the
IVR assay. After freeze-thaw, all of the nanocrystalline-
containing Brij 30 formulations had a significant difference
in the IVR profiles compared to that of the control liposomal
ciprofloxacin formulation; the similarity factors range from
31.9 to 46.1 (Table V). The normalized initial rate of release
was 51, 22, 25, 28 and 34% for the CFI control and the four
CFI formulations containing 0.05, 0.1, 0.2 and 0.3% Brij 30,
respectively, after freeze-thaw. The normalized initial rate of
release for all three nanocrystalline formulations was about
half that of the CFI control.
DISCUSSION
The application of nanotechnology approaches for treatment
of lung disease is an emerging area that has recently been
reviewed (23, 24). The ability to customize release rates of
these nanotechnology formulations by simple operations and
without any major qualitative or quantitative changes in the
composition of the drug product might be an attractive path
for personalized medicine (25). For example, the nature of
chronic lung infections varies even in the same individual over
time, and different individuals with the same disease may have
different strains of the same bacteria or a different set of co-
infections. Furthermore, the host immune system reacts to the
nature of the lung microbiome impacting the progression of
the disease (26). To get the optimum therapeutic response –
the balance of efficacy and safety – a more sophisticated ap-
proach to re-establish homeostasis in each individual patient
may be preferable to the ‘one size fits all’ therapeutic ap-
proach that is often necessitated by the nature of the current
pharmaceutical dosage forms and the regulatory approval
process for those medications.
With respect specifically to the example in this research,
liposomal ciprofloxacin is being developed as an inhaled ther-
apy to treat lung infections (4–6). While the release profile of
the current liposomal ciprofloxacin product in development,
Pulmaquin, appears to be appropriate for non-CF bronchiec-
tasis patients colonized with P. aeruginosa (4–6), there may be
other lung infections in this or other patient populations for
which a ‘fine tuning’ of ciprofloxacin release would be
Table V Similarity Factor Analysis (f2) for CFI Formulations Containing Various Amounts of Brij 30 After Freeze-Thaw Versus the CFI Control
Shaded cells indicate lack of similarity
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Table IV Similarity Factor Analysis (f2) for CFI Formulations Containing
Various Amounts of Brij 30 Before Freeze-Thaw Versus the CFI Control
Test Reference
Control 0.05% 0.10% 0.20% 0.30%
Control 100 93.4 90.3 84.6 72.7
0.05% 93.4 100 92.2 88.3 73.5
0.10% 90.3 92.2 100 91.8 78.7
0.20% 84.6 88.3 91.8 100 83.4
0.30% 72.7 73.5 78.7 83.4 100
desirable. For example, a higher early spike of ciprofloxacin
may be warranted to kill certain types of bacteria present in
the lungs; e.g., those with higherMIC values, and this could be
achieved by addition of polysorbate 20 or Brij 30 to the for-
mulation to increase the Bburst^ of antibiotic. For patients
with intracellular infections in their alveolar macrophages;
e.g., non TBmycobacteria, it may be desirable to delay release
until the macrophages have time to take up the liposomes. A
liposomal formulation containing drug nanocrystals thus
might be more efficacious for this patient population (12). A
simple freeze-thaw procedure to transform the drug into
nanocrystalline form prior to inhaled administration could
accomplish this goal (12). Other infectious states might ideally
be treated by a combination of both a high initial bolus and a
slower release profile which could be achieved by addition of
surfactant to the liposomal ciprofloxacin formulation prior to
freeze-thaw. In summary, we have described a number of
methodologies to tailor a liposomal formulation’s release pro-
file to personalize treatment.
It was previously shown that liposomal encapsulated cipro-
floxacin could be converted into nanocrystalline form follow-
ing freeze-thaw; the liposomes retained structural integrity to
freeze-thaw by the addition of a cryoprotectant, either sucrose
or trehalose (12). The addition of cryoprotectant is known to
limit mechanical damage to liposomes by ice crystals which
can cause vesicle rupture during freezing or thawing (27–29).
The current studies extend the previous results by investigat-
ing whether surfactant interactions could be used to alter the
solid state behavior of the encapsulated drug and thus further
modulate the drug release profile. In these studies the formu-
lations with the best stability and least loss of encapsulated
drug after freeze-thaw contained a 4:1 (w/w) ratio of sucrose
to lipid. A ratio of 2:1 (w/w) sucrose to lipid provided some
protective benefit but generally resulted in greater loss in en-
capsulated drug than for the formulations with higher levels of
sucrose (data not shown).
The mechanisms underlying the effect of the surfactants on
the release rate are not yet fully understood but it is possible to
form a coherent qualitative picture. In the previous studies
without surfactant it was generally observed that each lipo-
some contained only one nanocrystal after freeze-thaw (12).
The ‘one nanocrystal per liposome’ observation was also evi-
dent in the new studies for CFI formulations containing low
levels of polysorbate 20 (i.e., 0.05%) immediately after freeze-
thaw (Fig. 4a) and these liposomes retained their encapsulated
nanocrystal structures for at least 17 h post freeze-thaw
(Fig. 4c). The ‘one nanocrystal per liposome’ was also ob-
served for CFI formulations containing low concentrations
of Brij 30 (i.e., 0.05%) immediately after freeze-thaw
(Fig. 4k). Together, these observations suggest that the rate
of crystal growth within each liposome is very fast, occurring
within seconds of thawing. Another observation is that the
amount of unencapsulated drug generally increased after
freeze-thaw with increasing surfactant concentration for both
polysorbate 20 (Fig. 2) and Brij 30 (Fig. 3) compared to the
CFI samples without surfactant which had negligible drug loss
after freeze-thaw (Figs. 2 and 3).
Figure 8 provides a tentative explanation of the mecha-
nisms underlying these observations. The release-rate modu-
lating surfactant (either Brij 30 or Polysorbate 20) causes tran-
sient pore formation during the freezing and/or thawing steps
resulting in loss of encapsulated drug with greater drug loss for
higher surfactant concentrations. This is consistent with stud-
ies that show that at low surfactant concentrations, below the
liposome-solubilizing level, surfactant molecules can coopera-
tively assemble into structures which form transient pores in
liposomes, allowing release of drug prior to rapid restoration
of the membrane integrity (30–32). Higher levels of surfactant
would result in a greater number of pores being formed and
thus a greater loss of encapsulated drug.
The presence of moderate amounts of polysorbate 20 (e.g.,
0.1 and 0.2%) resulted in liposomes which retained their circu-
lar shape in cryo-TEM images after freeze-thaw (Fig. 4d and g).
The shape of the liposome appears to be the result of the
growth of the nanocrystal; long nanocrystals cause the lipo-
somes to elongate. Once a crystallization event is initiated, pre-
sumably the nanocrystal will continue to grow until the concen-
tration of ciprofloxacin within the vesicle falls below its solubil-
ity limit. For CFI containing 0.1 or 0.2% polysorbate 20, the
loss of encapsulated drug may result in shorter nanocrystals
which don’t perturb the vesicle shape from its initial circular
state.
For low surfactant levels (e.g., 0.05% polysorbate 20),
little drug may be released during freeze-thaw which may
result in nanocrystals growing larger than the original size of
the vesicles. This may lead to elongated vesicles (Fig. 4a) or
in some cases, vesicle rupture which will increase the
amount of non-encapsulated drug. From these studies it is
not possible to know how much of the non-encapsulated
drug is produced during the freeze-thaw event versus in re-
sponse to the growing nanocrystal. However, it appears that
freeze-thaw at −50°C results in a greater loss in encapsulat-
ed drug for CFI containing 0.05% polysorbate 20. These
studies were not designed to ascertain the cause of the in-
creased loss of encapsulated drug when frozen at −50°C
versus using liquid nitrogen. In contrast to the situation with
0.05% polysorbate 20, liposomes containing the same con-
centration of Brij 30 appear to bemore deformable and able
to accommodate the larger nanocrystals; thus, there may be
less vesicle rupture in response to the growth of the
nanocrystals and lower levels of released drug for low Brij
30 concentrations (Fig. 3).
An additional difference between the two surfactants was
observed when moderate amounts of surfactant (e.g., 0.2%
polysorbate 20 and 0.25% Brij 30) were used. For the CFI
formulation containing 0.2% polysorbate 20, after freeze-
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thaw the nanocrystals were tightly constrained within the lipo-
somes but the vesicle size was relatively unchanged. In con-
trast, in the presence of 0.25% Brij 30 the liposomes appeared
to expand to a greater size than was required to accommodate
the nanocrystals. This visual evidence suggests that the CFI
vesicles containing Brij 30 could more easily accommodate
larger nanocrystals without rupturing and thus explains the
higher drug encapsulation values for Brij 30.
The differences in the structure of these surfactants may
provide an explanation for the observations: Brij 30 and poly-
sorbate 20 both contain a hydrophobic tail of similar length,
while the polar head group for Brij 30 is much smaller than that
for polysorbate 20. This may explain why the liposome vesicles
incorporating the smaller Brij 30 surfactant molecules are able
to flexibly accommodate the growing ciprofloxacin crystals
while the vesicles incorporating the polysorbate 20 surfactant
molecules with their much larger polar head groups are more
constrained and may be less able to flex, leading to destabiliza-
tion and loss of encapsulated drug during nanocrystal growth.
After freeze-thaw, the CFI formulations containing surfac-
tant all had a population of empty vesicles and a population of
vesicles containing nanocrystals and the balance between these
two states presumably accounted for the changes in the release
profiles. Thus, both aspects of the IVR profile from the CFI
liposomes can be modified by polysorbate 20 (Figs. 5 and 6)
and Brij 30 (Fig. 7), i.e., the Bburst^ of drug at the initial time as
well as the subsequent slower release profile.
The presence of precipitated drug within liposomes has been
described previously for vincristine (13), doxorubicin (2, 14),
topotecan (2) and vinorelbin (2, 33). In contrast to these studies
where the ciprofloxacin formed nanocrystals in response to
freeze-thaw, in the other studies the drug formed precipitates
during the loading process. It has also been previously noted
that precipitated drug within liposome vesicles leads to a slower
release and a longer in vivo half-life (2, 13). The rationale for the
slower release has been the lower soluble intravesicular drug
concentration which is the driving force for drug transport
across the liposomemembrane (2, 13, 14, 33). If the rate of drug
dissolution is fast compared to transport across the lipid mem-
brane, then an almost zero order rate of release can be obtained
as was demonstrated for doxorubicin (14) and vinorelbin (33).
However, it was hypothesized that Bthe rate of dissolution
of the intravesicular precipitate could further modulate the
internal drug concentration and even become the rate limiting
Fig. 8 Proposed mechanism for surfactant vesicle interactions during freeze-thaw explain the changes in both vesicle size and drug encapsulation. During freeze-
thaw, ice crystals serve as nucleation sites for drug crystal formation. The presence of surfactant causes pore formation with release of drug during the freezing or
thawing steps. Higher concentrations of surfactant result in greater overall loss of drug and an increase in the population of empty liposomes. While there may be
multiple crystal nucleation events in each liposome, one crystal grows larger at the expense of the others resulting in only one drug nanocrystal per liposome.
During the drug crystal growth phase, for higher concentrations of polysorbate 20, the liposomes remain fairly circular due to less drug being present within the
vesicles leading to shorter nanocrystals. For low concentrations of polysorbate 20, the vesicles become more elongated to accommodate the longer drug crystal.
For Brij 30, the liposome vesicles increase in size due to their association with the surfactant and fully accommodate the growing drug crystal without becoming
elongated in shape.
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step for release^ (33). In this liposomal ciprofloxacin system,
different nanocrystalline structures were created by varying
the surfactant concentration. If drug dissolution were rate lim-
iting, then it would be likely that a change in crystalline char-
acter would lead to differences in the rate of drug release. The
nanocrystalline structures were shorter and smaller for the
CFI samples containing higher polysorbate 20 concentrations,
which might be expected to lead to faster rates of drug disso-
lution. However, the initial rate of release was unchanged
when accounting for the unencapsulated drug (Fig. 6). This
result suggests that dissolution may not be rate-limiting for the
liposomal systems containing nanocrystalline ciprofloxacin.
The association of the surfactant into the liposomemembrane
may further influence the membrane permeability and release
rate. Polysorbate 20 did not appear to modify the mebrane per-
meability. However, for Brij 30, the liposome vesicles remain
circular but become larger, even greater in size than appears to
be necessary to accommodate the nanocrystal (Fig. 4l). Increasing
concentrations of Brij 30 resulted in faster initial rates of release
from the encapsulated component (Fig. 7) which suggests that the
membrane permeability has also been modified. The possibility
that dissolution may be rate-limiting cannot be entirely
discounted: The faster initial rate of release for CFI containing
increasing Brij 30 concentrations could bemore rapid dissolution
from the shorter drug crystals at the higher surfactant concentra-
tions and not a change in the permeability of the bilayer.
The long term safety and tolerability of these liposomal cip-
rofloxacin formulations containing Brij 30 or polysorbate 20
surfactant, like every inhaled product, must be assessed in pre-
clinical animal toxicology studies prior to entry into clinical trials.
However, the presence of liposomes or surfactants in an inhaled
product should not be alarming as the lung is bathed in lung
surfactant composed of proteins, cholesterol and lipids (34).
Furthermore, a number of synthetic or natural Bsurfactants^
are approved for administration to the lungs to treat respiratory
distress syndrome including Infasurf®, Exosurf®, Survanta®,
Curosurf®, and Surfaxin® (35). Surfactants are also used to
formulate drug suspensions for delivery by nebulization.
Marketed metered dose inhaler (MDI) products also use surfac-
tants to improve formulation stability and delivery performance;
e.g., oleic acid, PVP, lecithin, and sorbitan oleates.
In conclusion, as previously reported (12), freeze-thawing of
liposomally encapsulated ciprofloxacin results in the formation
of nanocrystals of ciprofloxacin within the liposomal vesicles with
an attenuated ciprofloxacin release rate compared to the unfro-
zen liposomal formulation. Addition of certain types of surfac-
tants such as polysorbate 20 and Brij 30 can be used tomodulate
the release rates of ciprofloxacin from these nano-structures,
primarily by changing the ratio of the immediate release and
sustained release component. These simple operations with
modest changes to the qualitative and quantitative composition
of the formulation enable fine-tuning of the release rates that
may be utilized in personalizing medicines for the individual
needs of patients. Some of these liposome formulations contain-
ing ciprofloxacin nanocrystals are stable to nebulization and so
could be inhaled by patients with lung infections (23, 36).
CONCLUSIONS
We previously showed that the physical state of liposomal-
encapsulated ciprofloxacin can be converted to nanocrystalline
form following freeze-thaw. These drug nanocrystals introduce
a dissolution step and a lower intravesicular drug concentration
which reduces the concentration gradient for drug release com-
pared to that of the unfrozen control formulation. The size and
shape of the nanocrystals can be further adjusted by the addition
of a small amount of a surfactant, either 0.05 to 0.20% polysor-
bate 20 or 0.05 to 0.25% Brij 30, which results in shorter drug
nanocrystals within the liposome vesicles and an increase in
unencapsulated drug. The addition of surfactant thus allows
for further fine-tuning of the release profile by modifying the
ratio of the immediate release and sustained release component
as well as potentially changing the permeability of the bilayer.
These advances have the potential to transform inhaled
antiinfective therapy by providing methodologies that allow
the doctor or end user to modify the antibiotic release profile
to specifically address the needs of the patient.
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